Week in Review: WuXi AppTec and Juno Form China Immuno-Oncology JV

In a major cross-border deal, WuXi AppTec, China's largest CRO/CMO, and Juno Therapeutics of Seattle formed a joint venture to bring Juno's promising immuno-oncology drugs to China; Sorrento Therapeutics of San Diego raised $150 million in a private placement led by Ally Bridge Group, a China-US PE firm; Ally Bridge also participated in a funding of LinkDoc Technology, a Beijing company gathering cancer medical records on the cloud; Essex Bio of Zhuhai partnered with Abpro of Massachusetts to co-develop several mAbs in immuno-oncology and ophthalmology; the Institut Pasteur of Shanghai at the Chinese Academy of Sciences joined up with London's MRC Technology to speed China-discovered antibodies into approved drugs; BioChain, a US-China company, in-licensed China rights to a novel blood-based lung cancer diagnostic from Epigenomics of Germany; Alibaba ended plans to transfer its online pharmacy operations into Alibaba Health Information Technology; Hanmi Pharma of South Korea will spend $200 million to build a second China manufacturing facility; and Beijing's CANbridge Life Sciences filed an application with the Taiwan FDA for a Phase I/II trial of a novel brain cancer immunotherapy. More details.... Stock Symbols: (NSDQ: JUNO) (NSDQ: SRNE) (HK: 1061) (NYSE: BABA) (HK: 0241) (KS: 128940) Share this with colleagues: // //